sugammadex + neostigmine

sugammadex + neostigmine-Assuta Hospital Systems refers to a clinical trial comparison (NCT02441309) conducted by Assuta Hospital Systems evaluating two distinct pharmacological strategies for the reversal of neuromuscular blockade in morbidly obese patients undergoing bariatric surgery. Sugammadex is a selective relaxant binding agent (SRBA), a modified gamma-cyclodextrin that encapsulates steroidal neuromuscular blocking agents (NMBAs) like rocuronium and vecuronium to rapidly reverse their effects. Neostigmine is an acetylcholinesterase inhibitor that increases the concentration of acetylcholine at the neuromuscular junction to compete with NMBAs; it is typically co-administered with an antimuscarinic agent like atropine to prevent systemic muscarinic side effects such as bradycardia. The study specifically compares the speed of recovery and safety profiles of these two reversal agents in the high-risk bariatric surgical population.